AC Immune (ACIU) Current Leases (2019 - 2026)
AC Immune (ACIU) posted quarterly Current Leases of $1.1 billion for Q1 2026, up 91594.54% year-over-year from N/an in Q1 2025, and down 1.17% quarter-over-quarter from $1.1 billion in Q4 2025.
AC Immune (ACIU) Current Leases (2019 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Current Leases for 8 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 91594.54% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 91594.54% YoY), while the FY2025 annual figure was $1.0 billion, up 87640.8% from the prior year.
- Current Leases retreated to $1.1 billion in Q1 2026 per ACIU's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Current Leases topped out at $1.1 billion in Q4 2025 and bottomed at $568836.0 in Q4 2022.
- Historically, Current Leases has averaged $241.6 million across 5 years, with a median of $1.1 million in 2025.
- Annual changes were most pronounced in 2022 — Current Leases slumped 99.91% — and 2023, when it surged 133081.13%.
- AC Immune's Current Leases stood at $568836.0 in 2022, then surged by 133081.13% to $757.6 million in 2023, then slumped by 99.85% to $1.2 million in 2024, then soared by 90917.36% to $1.1 billion in 2025, then fell by 1.17% to $1.1 billion in 2026.
- Business Quant data shows ACIU's Current Leases at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 1.07 Bn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 801,019.83 |
| Jun 30, 2024 | 759,680.13 |
| Mar 31, 2024 | 769,898.52 |
| Dec 31, 2023 | 757.58 Mn |
| Sep 30, 2023 | 628,344.67 |
| Jun 30, 2023 | 615,033.08 |
| Mar 31, 2023 | 595,720.58 |
| Dec 31, 2022 | 568,836.01 |
| Sep 30, 2022 | 601,600.30 |
| Jun 30, 2022 | 599.10 Mn |
| Mar 31, 2022 | 620.45 Mn |
| Dec 31, 2021 | 618.17 Mn |
| Sep 30, 2021 | 628.43 Mn |